Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zilovertamab + docetaxel
- Development stage
- Unknown
- Lead developer
- Ho'ola Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Zilovertamab + docetaxel is an investigational combination therapy being evaluated for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Zilovertamab (formerly cirmtuzumab) is a humanized monoclonal antibody that specifically targets Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1), an onco-embryonic surface protein that is highly expressed in various malignancies, including prostate cancer, but is not expressed on normal adult tissues. By binding to ROR1, zilovertamab inhibits the non-canonical Wnt5a signaling pathway, which drives tumor cell survival, stemness, and metastasis. Docetaxel is a standard-of-care taxane chemotherapy that binds to beta-tubulin, stabilizing microtubules and preventing their disassembly, which leads to cell cycle arrest in the G2/M phase and subsequent apoptosis. The combination is hypothesized to enhance anti-tumor activity by simultaneously inhibiting ROR1-mediated survival signals and inducing mitotic arrest.
- Brand names
- Taxotere
- Other names
- cirmtuzumab + docetaxelzilovertamab and docetaxel
02
Targets
ROR1 (Receptor tyrosine kinase-like orphan receptor 1)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on zilovertamab + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zilovertamab + docetaxel.